Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010 (2010), Article ID 650794, 16 pages
http://dx.doi.org/10.4061/2010/650794
Research Article

Effects of Various Flavonoids on the -Synuclein Fibrillation Process

1Department of Chemistry, University of California, Santa Cruz, CA 95064, USA
2Center for Computational Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, Institute for Intrinsically Disordered Protein Research, Indiana University School of Medicine, 410 W. 10th Street, HS 5009, Indianapolis, IN 46202, USA
3Institute for Biological Instrumentation, Russian Academy of Sciences, Pushchino, Moscow 142290, Russia

Received 26 May 2009; Revised 8 September 2009; Accepted 23 October 2009

Academic Editor: Mark Robert Cookson

Copyright © 2010 Xiaoyun Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. de Rijk, C. Tzourio, M. M. Breteler et al., “Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 62, no. 1, pp. 10–15, 1997. View at Publisher · View at Google Scholar
  2. S. B. Dunnett and A. Bjorklund, “Prospects for new restorative and neuroprotective treatments in Parkinson's disease,” Nature, vol. 399, pp. A32–A39, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. L. S. Forno, “Neuropathology of Parkinson's disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 3, pp. 259–272, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839–840, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Eriksen, Z. Wszolek, and L. Petrucelli, “Molecular pathogenesis of Parkinson disease,” Archives of Neurology, vol. 62, no. 3, pp. 353–357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Eriksen, T. M. Dawson, D. W. Dickson, and L. Petrucelli, “Caught in the act: α-synuclein is the culprit in Parkinson's disease,” Neuron, vol. 40, no. 3, pp. 453–456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Selkoe, “Translating cell biology into therapeutic advances in Alzheimer's disease,” Nature, vol. 399, pp. A23–A31, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Kosaka and E. Iseki, “Dementia with Lewy bodies,” Current Opinion in Neurology, vol. 9, no. 4, pp. 271–275, 1996. View at Google Scholar · View at Scopus
  9. J. Q. Trojanowski and V. M. Lee, “Parkinson's disease and related α-synucleinopathies are brain amyloidoses,” Annals of the New York Academy of Sciences, vol. 991, pp. 107–110, 2003. View at Google Scholar · View at Scopus
  10. K. K. Dev, K. Hofele, S. Barbieri, V. L. Buchman, and H. van der Putten, “Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease,” Neuropharmacology, vol. 45, no. 1, pp. 14–44, 2003. View at Publisher · View at Google Scholar
  11. V. N. Uversky, “Neuropathology, biochemistry, and biophysics of α-synuclein aggregation,” Journal of Neurochemistry, vol. 103, no. 1, pp. 17–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. G. Spillantini, R. A. Crowther, R. Jakes, N. J. Cairns, P. L. Lantos, and M. Goedert, “Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies,” Neuroscience Letters, vol. 251, no. 3, pp. 205–208, 1998. View at Google Scholar · View at Scopus
  13. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, “α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6469–6473, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the a-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar
  15. R. Kruger, W. Kuhn, T. Muller et al., “Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar
  17. K. A. Conway, S. J. Lee, J. C. Rochet et al., “Accelerated oligomerization by Parkinson's disease linked a-synuclein mutants,” Annals of the New York Academy of Sciences, vol. 920, pp. 42–45, 2000. View at Google Scholar · View at Scopus
  18. J. Li, V. N. Uversky, and A. L. Fink, “Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein,” Biochemistry, vol. 40, no. 38, pp. 11604–11613, 2001. View at Publisher · View at Google Scholar
  19. M. C. Chartier-Harlin, J. Kachergus, C. Roumier et al., “a-synuclein locus duplication as a cause of familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004. View at Publisher · View at Google Scholar
  20. A. B. Singleton, M. Farrer, J. Johnson et al., “a-synuclein locus triplication causes Parkinson's disease,” Science, vol. 302, no. 5646, p. 841, 2003. View at Publisher · View at Google Scholar
  21. M. J. Volles and P. T. Lansbury Jr., “Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease,” Biochemistry, vol. 42, no. 26, pp. 7871–7878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. H. A. Lashuel, B. M. Petre, J. Wall et al., “a-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils,” Journal of Molecular Biology, vol. 322, no. 5, pp. 1089–1102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Volles and P. T. Lansbury Jr., “Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism,” Biochemistry, vol. 41, no. 14, pp. 4595–4602, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. T. T. Ding, S. J. Lee, J. C. Rochet, and P. T. Lansbury Jr., “Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes,” Biochemistry, vol. 41, no. 32, pp. 10209–10217, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Anguiano, R. J. Nowak, and P. T. Lansbury Jr., “Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes,” Biochemistry, vol. 41, no. 38, pp. 11338–11343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Arispe, “Architecture of the Alzheimer's A β P ion channel pore,” Journal of Membrane Biology, vol. 197, no. 1, pp. 33–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Demuro, E. Mina, R. Kayed, S. C. Milton, I. Parker, and C. G. Glabe, “Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17294–17300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. D. Green, L. Kreplak, C. Goldsbury et al., “Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide,” Journal of Molecular Biology, vol. 342, no. 3, pp. 877–887, 2004. View at Publisher · View at Google Scholar
  29. M. A. Findeis, “Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization,” Biochimica et Biophysica Acta, vol. 1502, no. 1, pp. 76–84, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. N. R. Cashman and B. Caughey, “Prion diseases—close to effective therapy?” Nature Reviews Drug Discovery, vol. 3, no. 10, pp. 874–884, 2004. View at Publisher · View at Google Scholar
  31. V. Heiser, E. Scherzinger, A. Boeddrich et al., “Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6739–6744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Pickhardt, Z. Gazova, M. von Bergen et al., “Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells,” Journal of Biological Chemistry, vol. 280, no. 5, pp. 3628–3635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Taniguchi, N. Suzuki, M. Masuda et al., “Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins,” Journal of Biological Chemistry, vol. 280, no. 9, pp. 7614–7623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. P. G. Pietta, “Flavonoids as antioxidants,” Journal of Natural Products, vol. 63, no. 7, pp. 1035–1042, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Porat, A. Abramowitz, and E. Gazit, “Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism,” Chemical Biology and Drug Design, vol. 67, no. 1, pp. 27–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A. L. Fink, “The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils,” Journal of Biological Chemistry, vol. 279, no. 26, pp. 26846–26857, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Li, M. Zhu, S. Rajamani, V. N. Uversky, and A. L. Fink, “Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils,” Chemical Biology, vol. 11, no. 11, pp. 1513–1521, 2004. View at Publisher · View at Google Scholar
  38. D.-P. Hong, A. L. Fink, and V. N. Uversky, “Structural characteristics of the α-synuclein oligomers stabilized by the flavonoid baicalein,” Journal of Molecular Biology, vol. 383, no. 1, pp. 214–223, 2008. View at Publisher · View at Google Scholar
  39. E. Middleton Jr., C. Kandaswami, and T. C. Theoharides, “The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer,” Pharmacological Reviews, vol. 52, no. 4, pp. 673–751, 2000. View at Google Scholar
  40. R. A. Larson, “The antioxidants of higher plants,” Phytochemistry, vol. 27, no. 4, pp. 969–978, 1988. View at Publisher · View at Google Scholar · View at Scopus
  41. S. V. Jovanovic, S. Steenken, Y. Hara, and M. G. Simic, “Reduction potentials of flavonoid and model phenoxyl radicals. Which ring in flavonoids is responsible for antioxidant activity?” Journal of the Chemical Society, Perkin Transactions, vol. 2, pp. 2497–2504, 1996. View at Google Scholar
  42. G. R. Buettner, “The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate,” Archives of Biochemistry and Biophysics, vol. 300, no. 2, pp. 535–543, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Robak and R. J. Gryglewski, “Flavonoids are scavengers of superoxide anions,” Biochemical Pharmacology, vol. 37, no. 5, pp. 837–841, 1988. View at Publisher · View at Google Scholar · View at Scopus
  44. S. R. Husain, J. Cillard, and P. Cillard, “Hydroxyl radical scavenging activity of flavonoids,” Phytochemistry, vol. 26, no. 9, pp. 2489–2491, 1987. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Torel, J. Cillard, and P. Cillard, “Antioxidant activity of flavonoids and reactivity with peroxy radical,” Phytochemistry, vol. 25, no. 2, pp. 383–385, 1986. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Gutteridge and B. Halliwell, “Free radicals and antioxidants in the year 2000. A historical look to the future,” Annals of the New York Academy of Sciences, vol. 899, pp. 136–147, 2000. View at Google Scholar · View at Scopus
  47. D. Amic, D. Davidovic-Amic, D. Beslo, and N. Trinajstic, “Structure-radical scavenging activity relationships of flavonoids,” Croatica Chemica Acta, vol. 76, no. 1, pp. 55–61, 2003. View at Google Scholar · View at Scopus
  48. J. Nordberg and E. S. Arner, “Reactive oxygen species, antioxidants, and the mammalian thioredoxin system,” Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1287–1312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. M. N. Patel, “Oxidative stress, mitochondrial dysfunction, and epilepsy,” Free Radical Research, vol. 36, no. 11, pp. 1139–1146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. D. A. Butterfield and J. Kanski, “Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins,” Mechanisms of Ageing and Development, vol. 122, no. 9, pp. 945–962, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. B. I. Giasson, J. E. Duda, I. V. Murray et al., “Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions,” Science, vol. 290, no. 5493, pp. 985–989, 2000. View at Publisher · View at Google Scholar
  52. B. I. Giasson, H. Ischiropoulos, V. M. Lee, and J. Q. Trojanowski, “The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases,” Free Radical Biology and Medicine, vol. 32, no. 12, pp. 1264–1275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Zhang, V. L. Dawson, and T. M. Dawson, “Oxidative stress and genetics in the pathogenesis of parkinson's disease,” Neurobiology of Disease, vol. 7, no. 4, pp. 240–250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Okawa, J. Kinjo, T. Nohara, and M. Ono, “DPPH (1,1-diphenyl-2-Picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants,” Biological and Pharmaceutical Bulletin, vol. 24, no. 10, pp. 1202–1205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. C. G. Heijnen, G. R. Haenen, F. A. van Acker, W. J. van der Vijgh, and A. Bast, “Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups,” Toxicology in Vitro, vol. 15, no. 1, pp. 3–6, 2001. View at Publisher · View at Google Scholar
  56. C. G. Heijnen, G. R. Haenen, R. M. Oostveen, E. M. Stalpers, and A. Bast, “Protection of flavonoids against lipid peroxidation: the structure activity relationship revisited,” Free Radical Research, vol. 36, no. 5, pp. 575–581, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Arora, M. G. Nair, and G. M. Strasburg, “Structure-activity relationships for antioxidant activities of a series of flavonoids in a liposomal system,” Free Radical Biology and Medicine, vol. 24, no. 9, pp. 1355–1363, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Di Carlo, N. Mascolo, A. A. Izzo, and F. Capasso, “Flavonoids: old and new aspects of a class of natural therapeutic drugs,” Life Sciences, vol. 65, no. 4, pp. 337–353, 1999. View at Publisher · View at Google Scholar
  59. W. Bors, W. Heller, C. Michel, and M. Saran, “Radical chemistry of flavonoid antioxidants,” Advances in Experimental Medicine and Biology, vol. 264, pp. 165–170, 1990. View at Google Scholar · View at Scopus
  60. W. Bors, W. Heller, C. Michel, and M. Saran, “Flavonoids as antioxidants: determination of radical-scavenging efficiencies,” Methods in Enzymology, vol. 186, pp. 343–355, 1990. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Nielsen, S. Frokjaer, J. Brange, V. N. Uversky, and A. L. Fink, “Probing the mechanism of insulin fibril formation with insulin mutants,” Biochemistry, vol. 40, no. 28, pp. 8397–8409, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. J. A. Joseph, B. Shukitt-Hale, N. A. Denisova et al., “Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation,” Journal of Neuroscience, vol. 19, no. 18, pp. 8114–8121, 1999. View at Google Scholar · View at Scopus
  63. D. Commenges, V. Scotet, S. Renaud, H. Jacqmin-Gadda, P. Barberger-Gateau, and J. F. Dartigues, “Intake of flavonoids and risk of dementia,” European Journal of Epidemiology, vol. 16, no. 4, pp. 357–363, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Levites, O. Weinreb, G. Maor, M. B. Youdim, and S. Mandel, “Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration,” Journal of Neurochemistry, vol. 78, no. 5, pp. 1073–1082, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Griffioen, H. Duhamel, N. van Damme et al., “A yeast-based model of a-synucleinopathy identifies compounds with therapeutic potential,” Biochimica et Biophysica Acta, vol. 1762, no. 3, pp. 312–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. K. A. Conway, J. D. Harper, and P. T. Lansbury, “Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp. 1318–1320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Sang, J. D. Lambert, and C. S. Yang, “Bioavailability and stability issues in understanding the cancer preventive effects of tea polyphenols,” Journal of the Science of Food and Agriculture, vol. 86, no. 14, pp. 2256–2265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Meng, L. A. Munishkina, A. L. Fink, and V. N. Uversky, “Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation,” Biochemistry, vol. 48, no. 34, pp. 8206–8224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Lebeau, F. Esclaire, W. Rostene, and D. Pelaprat, “Baicalein protects cortical neurons from β-amyloid (25–35) induced toxicity,” Neuroreport, vol. 12, no. 10, pp. 2199–2202, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. E. K. Perry, A. T. Pickering, W. W. Wang, P. J. Houghton, and N. S. Perry, “Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy,” Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 527–534, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. C. M. Watanabe, S. Wolffram, P. Ader et al., “The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6577–6580, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. M. G. Hertog, E. J. Feskens, P. C. Hollman, M. B. Katan, and D. Kromhout, “Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study,” The Lancet, vol. 342, no. 8878, pp. 1007–1011, 1993. View at Publisher · View at Google Scholar · View at Scopus
  73. M. G. Hertog, D. Kromhout, C. Aravanis et al., “Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study,” Archives of Internal Medicine, vol. 155, no. 4, pp. 381–386, 1995. View at Publisher · View at Google Scholar
  74. E. B. Rimm, M. B. Katan, A. Ascherio, M. J. Stampfer, and W. C. Willett, “Relation between intake of flavonoids and risk for coronary heart disease in male health professionals,” Annals of Internal Medicine, vol. 125, no. 5, pp. 384–389, 1996. View at Google Scholar · View at Scopus
  75. R. J. Williams, J. P. Spencer, and C. Rice-Evans, “Flavonoids: antioxidants or signalling molecules?” Free Radical Biology and Medicine, vol. 36, no. 7, pp. 838–849, 2004. View at Publisher · View at Google Scholar
  76. B. Frei and J. V. Higdon, “Antioxidant activity of tea polyphenols in vivo: evidence from animal studies,” Journal of Nutrition, vol. 133, no. 10, pp. 3275S–3284S, 2003. View at Google Scholar · View at Scopus
  77. B. Zhao, “Natural antioxidants for neurodegenerative diseases,” Molecular Neurobiology, vol. 31, no. 1–3, pp. 283–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. J. P. Spencer, C. Rice-Evans, and R. J. Williams, “Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability,” Journal of Biological Chemistry, vol. 278, no. 37, pp. 34783–34793, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Masuda, N. Suzuki, S. Taniguchi et al., “Small molecule inhibitors of a-synuclein filament assembly,” Biochemistry, vol. 45, no. 19, pp. 6085–6094, 2006. View at Publisher · View at Google Scholar · View at Scopus